Nuvation Bio Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Nuvation Bio amended its license agreement with Daiichi Sankyo (effective April 1, 2026) to add Japan to its licensed territory for the compound DS-1001b. Nuvation acquired AnHeart (which held the original September 2020 license) on April 9, 2024. Key changes: Nuvation pays [redacted] upfront for Japan expansion; receives royalty-bearing exclusive rights in Japan; assumes development, manufacturing, and commercialization responsibilities there; and gains access to Safusidenib Data and clinical trial data. Daiichi retains limited rights in Japan for [redacted] purposes only.
Why this rating
Amendment expands territory but specific financial terms redacted. Japan addition represents geographic expansion of existing asset; moderate relative to $497M market cap; execution risk remains.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.